December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

43.83 -0.21 (-0.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars ↗
Exelixis' STELLAR-303 trial shows zanzalintinib plus Tecentriq improved survival in colorectal cancer, with no new safety concerns reported. 
Via Benzinga
News headline image
AMD To Rally More Than 36%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug ↗
Shares surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study. 
Via Investor's Business Daily
News headline image
What 9 Analyst Ratings Have To Say About Exelixis ↗
 
Via Benzinga
News headline image
Analyst Expectations For Exelixis's Future ↗
 
Via Benzinga
News headline image
Price Over Earnings Overview: Exelixis ↗
 
Via Benzinga
News headline image
These stocks are moving in today's pre-market session ↗
Discover the top movers in Monday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Sequans Communications Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
News headline image
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors ↗
EXELIXIS INC (NASDAQ:EXEL) meets key growth investing criteria with strong earnings, revenue growth, and profitability, making it a standout for investors following Louis Navellier's strategy. 
Via Chartmill
News headline image
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation ↗
EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and reasonable valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector. 
Via Chartmill
News headline image
DoorDash To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in Undervalued Biotech Stocks ↗
EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, growth, and financial health, making it a compelling pick for value investors. 
Via Chartmill
News headline image
EXELIXIS INC (NASDAQ:EXEL) – A High-Growth Momentum Stock with Strong Technical Setup ↗
EXELIXIS INC (NASDAQ:EXEL) combines strong earnings momentum with a high technical rating, making it a standout for growth investors. The stock's breakout setup suggests potential upside. 
Via Chartmill
News headline image
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Technical Breakout Potential ↗
EXELIXIS INC (NASDAQ:EXEL) shows strong growth fundamentals and a bullish technical setup, making it a stock worth watching for investors seeking growth opportunities. 
Via Chartmill
News headline image
2 Top Stocks to Buy With Less Than $100 ↗
Via The Motley Fool
News headline image
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender for Growth Investors ↗
EXELIXIS INC (NASDAQ:EXEL) shows strong earnings growth, expanding margins, and solid cash flow, making it a standout for growth investors following Louis Navellier’s strategy. 
Via Chartmill
News headline image
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June
From Exelixis, Inc.
Via Business Wire
News headline image
EXELIXIS INC (NASDAQ:EXEL) – A Strong Growth Stock with Attractive Valuation ↗
EXELIXIS INC (NASDAQ:EXEL) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the biotech sector. 
Via Chartmill
News headline image
EXELIXIS INC (NASDAQ:EXEL) – An Undervalued Biotech Stock with Strong Fundamentals ↗
EXELIXIS INC (NASDAQ:EXEL) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a candidate for value investors. 
Via Chartmill
News headline image
CoreWeave, Super Micro Computer And Coinbase Are Among Top 11 Large-Cap Gainers Last Week (May 12-May 16): Are The Others In Your Portfolio? ↗
Large-cap stocks surged in the last week. CoreWeave, Super Micro, Coinbase, NRG Energy, Astera Labs, First Solar, Exelixis, Rocket Lab, Hims & Hers, On Holding and Gap were the top performers. 
Via Benzinga
News headline image
EXELIXIS INC (NASDAQ:EXEL) – A Strong Contender in High Growth Momentum and Minervini’s Trend Template ↗
EXELIXIS INC (NASDAQ:EXEL) meets Minervini’s Trend Template with strong technicals and high growth momentum, making it a standout in biotech. Review its full technical and fundamental strengths before... 
Via Chartmill
News headline image
9 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Demystifying Exelixis: Insights From 8 Analyst Reviews ↗
 
Via Benzinga
News headline image
Exelixis Stock Soars As Analysts Applaud Raised 2025 Guidance, Q1 Earnings Beat ↗
Exelixis lifts 2025 revenue outlook after strong Q1 driven by Cabometyx sales surge and early traction in the neuroendocrine tumor market. 
Via Benzinga
News headline image
Tech Stocks Edge Up, AMD Rallies 5%, 30-Year Yields Eye Danger Zone: What's Driving Markets Wednesday? ↗
Nasdaq 100 rises further as Nvidia and AMD rally on Middle East investment hopes, while gold tumbles and Treasury yields surge. 
Via Benzinga
News headline image
Why Exelixis Stock Is Skyrocketing Today ↗
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.